The Indication That Opened the Door
In 1957, the FDA approved G.D. Searle’s hormone pill Enovid to treat menstrual disorders—not to prevent pregnancy. That distinction was central to how the drug entered the market. Its active hormones could suppress ovulation, but the approved label described a medical use rather than contraception.
One Pill, Two Uses
A drug’s approval is tied to the uses its maker asks regulators to evaluate and authorize. Once Enovid was available, physicians could prescribe it for another purpose—a practice called off-label prescribing. The FDA did not need to approve every individual prescription, so doctors could use the pill as a contraceptive even though that use was not yet on its official label.
The strategy was not simply a label trick: the pill had been studied for pregnancy prevention, and the FDA later approved Enovid specifically as a contraceptive in 1960. But the earlier menstrual-disorder approval provided a lawful route for the drug to reach doctors and patients before that formal indication was granted.
What Changed in 1960
The key shift was not that the pill suddenly began working differently. Rather, contraception became an expressly approved use, making the drug’s purpose clear in its official labeling. The episode shows how a distinction in regulatory language—what a medicine is approved to treat versus how a doctor may prescribe it—helped bring the first oral contraceptive into medical practice.
